伊尔贝萨坦和勃起功能障碍之间的关联:综合分析,包括现实世界药物监测和门德尔随机化
Kaiqin Chen1, Rui Cheng1, Jian Guo1
1Xiang'an Hospital of Xiamen University, Xia Men, Fu Jian, China.
Hospital pharmacy
|October 20, 2025
概括
伊尔贝萨坦的使用与勃起功能障碍 (ED) 有关. 这项研究结合了现实世界的数据和遗传分析,以找到潜在的因果关系,表明ED可能是副作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
- 公共卫生 公共卫生
背景情况:
- 伊尔贝沙坦是一种常见的高血压药物.
- 伊尔贝萨坦和勃起功能障碍 (ED) 之间的联系需要进一步调查.
研究的目的:
- 探索伊尔贝萨坦和ED之间的关联.
- 通过药物监测和门德尔随机化评估潜在的因果关系.
主要方法:
- 使用ROR,PRR,BCPNN和GPS进行药监测分析.
- 孟德尔的随机化分析与反向差异加权.
主要成果:
- 药监测分析显示,伊尔贝萨坦和ED之间存在显著的关联.
- 门德尔的随机化也表明了显著的相关性,支持因果关系.
结论:
- 伊尔贝萨坦的使用与ED有显著的关联.
- 勃起障碍应该被认为是伊尔贝沙坦的潜在不良影响,需要进一步的研究和临床监测.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
249
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
249
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
928
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
928
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
Dose-Response Relationship: Potency and Efficacy
6.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.3K

